share_log

Tharimmune | 10-Q: Q3 2024 Earnings Report

Tharimmune | 10-Q: Q3 2024 Earnings Report

Tharimmune | 10-Q:2024財年三季報
美股SEC公告 ·  11/08 06:29

牛牛AI助理已提取核心訊息

Tharimmune, a clinical-stage biotechnology company, reported a net loss of $8,377,018 for the nine months ended September 30, 2024, compared to a net loss of $6,845,317 for the same period in 2023. The company's net cash used in operating activities was $7,868,344 for the nine months ended September 30, 2024, while net cash provided by financing activities amounted to $1,707,229. Tharimmune's cash balance decreased to $4,774,237 at the end of the period from $10,935,352 at the beginning of the period. The company has been actively developing its product pipeline, including entering into a patent license agreement for TH104 and TH103, and a separate agreement for INT-023/TH023. Tharimmune plans to initiate a Phase 2 trial for TH104 and is developing other therapeutic candidates targeting immuno-oncology targets such as HER2, HER3, and PD-1. The company...Show More
Tharimmune, a clinical-stage biotechnology company, reported a net loss of $8,377,018 for the nine months ended September 30, 2024, compared to a net loss of $6,845,317 for the same period in 2023. The company's net cash used in operating activities was $7,868,344 for the nine months ended September 30, 2024, while net cash provided by financing activities amounted to $1,707,229. Tharimmune's cash balance decreased to $4,774,237 at the end of the period from $10,935,352 at the beginning of the period. The company has been actively developing its product pipeline, including entering into a patent license agreement for TH104 and TH103, and a separate agreement for INT-023/TH023. Tharimmune plans to initiate a Phase 2 trial for TH104 and is developing other therapeutic candidates targeting immuno-oncology targets such as HER2, HER3, and PD-1. The company anticipates IND-enabling studies for TH3215, TH0059, and TH1940 in the coming years. Tharimmune also entered into a nonbinding letter of intent to acquire Intract Pharma Limited, which would enhance its oral biologics capabilities. The company's future plans include advancing its clinical and preclinical candidates, seeking strategic collaborations, and potentially engaging in M&A activities to maximize pipeline value.
生物技術公司Tharimmune報告稱,在2024年9月30日結束的九個月中,淨虧損爲8,377,018美元,而2023年同期淨虧損爲6,845,317美元。該公司的經營活動中使用的淨現金爲2024年9月30日結束的九個月中爲7,868,344美元,而融資活動中提供的淨現金爲1,707,229美元。Tharimmune的現金餘額從該期初的10,935,352美元下降至期末的4,774,237美元。該公司一直在積極開發其產品管道,包括簽署了TH104和TH103的專利許可協議,以及另一份INt-023/TH023的協議。Tharimmune計劃開始對TH104進行第2階段試驗,並正在開發其他針對...展開全部
生物技術公司Tharimmune報告稱,在2024年9月30日結束的九個月中,淨虧損爲8,377,018美元,而2023年同期淨虧損爲6,845,317美元。該公司的經營活動中使用的淨現金爲2024年9月30日結束的九個月中爲7,868,344美元,而融資活動中提供的淨現金爲1,707,229美元。Tharimmune的現金餘額從該期初的10,935,352美元下降至期末的4,774,237美元。該公司一直在積極開發其產品管道,包括簽署了TH104和TH103的專利許可協議,以及另一份INt-023/TH023的協議。Tharimmune計劃開始對TH104進行第2階段試驗,並正在開發其他針對免疫腫瘤靶點如HER2、HER3和PD-1的治療候選藥物。未來幾年,公司預計爲TH3215、TH0059和TH1940進行IND準備研究。Tharimmune還簽署了一份非約束性意向書,擬收購Intract Pharma Limited,以增強其口服生物製品能力。公司未來的計劃包括推進其臨床和臨床前候選藥物,尋求戰略合作,以及可能參與併購活動,以最大化管道價值。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。